HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Feinstein, EWG Gunning For Spring Senate Hearing On Cosmetics Bill

This article was originally published in The Rose Sheet

Executive Summary

During a March 1 press call, the Environmental Working Group highlighted findings from an 800-person survey indicating that 68% of men and women likely to vote this fall support increased government oversight of cosmetic chemicals. Senator Dianne Feinstein touted her proposed Personal Care Products Safety Act as the answer to consumer concerns, hopeful that a Senate committee hearing will be held in the spring.

You may also be interested in...

EWG’s Mary Kay Initiative For The PCPSA: Tactical Blitz Or Hail Mary?

The Environmental Working Group is targeting messaging to independent sales reps at Mary Kay’s annual seminar in an effort to rally support behind the Personal Care Products Safety Act. But Mary Kay’s beef with the proposed bill largely centers on federal preemption, an issue the Personal Care Products Council has suggested will likely drive reform negotiations in the 115th Congress.

FDA Seeks Info From Injured WEN Users, Docs As Investigation Continues

As recently reported by The Rose Sheet, FDA continues to investigate more than 21,000 adverse-event reports from users of WEN Cleansing Conditioners, marketed by Chaz Dean and Guthy-Renker, LLC. The agency published an alert July 19, noting that the cause of the AEs is still not known, and issued a call to consumers and health care providers for information that could help to fill in the blanks.

PCPSA's 'No Harm' Standard Would Set High Bar For FDA Ingredient Review

Regulatory consultants have concerns about the draft Personal Care Products Safety Act's proposed standard for FDA ingredient review – reasonable certainty of no harm. The standard's de facto application in FDA's review of new dietary ingredients in the supplement space has resulted in a fail rate of around 75%.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts